文献速递消化道肿瘤与早癌

全基因组DNA甲基化分析揭示非转移性结直肠癌的预后分类器(ProMCol分类器)

Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier).
PubMed 文献 · Gut · 2017-11-03

本研究对两个非转移性结直肠癌队列(筛选队列n=572,验证队列n=274)进行全基因组DNA甲基化分析,基于20个CpG位点的主成分分析构建ProMCol预后分类器。该分类器与总生存期在筛选队列(HR 0.51,95%CI 0.41-0.63,p=6.2E-10)和验证队列(HR 0.61,95%CI 0.45-0.82,p=0.001)中相关,并将3年总生存期预测误差从0.127降至0.120,4年从0.153降至0.140。

要点

  • ProMCol分类器基于20个CpG位点构建,与筛选队列总生存期相关(HR 0.51,95%CI 0.41-0.63)。
  • 验证队列中分类器与总生存期相关(HR 0.61,95%CI 0.45-0.82,p=0.001)。
  • 联合分类器后3年总生存期预测误差从0.127降至0.120,4年从0.153降至0.140。

核心结论

  • ProMCol分类器可提高非转移性结直肠癌患者的预后准确性。

研究设计与样本

  • 全基因组DNA甲基化研究,纳入两个非转移性结直肠癌队列:筛选队列n=572,验证队列n=274。
  • 在筛选队列中基于Cox模型的边际检验筛选预后CpG位点,并利用34对肿瘤与正常黏膜组织的甲基化差异作为辅助协变量通过独立假设加权调整p值。
  • 从调整后p值最小的1000个CpG位点中,选择总生存期Brier评分最小的20个CpG位点,应用主成分分析构建ProMCol分类器。

主要发现

  • ProMCol分类器与筛选队列总生存期相关(HR 0.51,95%CI 0.41-0.63,p=6.2E-10)。
  • ProMCol分类器与验证队列总生存期相关(HR 0.61,95%CI 0.45-0.82,p=0.001)。
  • 独立验证显示,仅用标准临床变量计算的3年总生存期预测误差为0.127,联合分类器后降至0.120;4年总生存期预测误差从0.153降至0.140。
  • 所有结果在疾病特异性生存期分析中得到确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pathological staging used for the prediction of patient survival in colorectal cancer (CRC) provides only limited information. DESIGN: Here, a genome-wide study of DNA methylation was conducted for two cohorts of patients with non-metastatic CRC (screening cohort (n=572) and validation cohort (n=274)). A variable screening for prognostic CpG sites was performed in the screening cohort using marginal testing based on a Cox model and subsequent adjustment of the p-values via independent hypothesis weighting using the methylation difference between 34 pairs of tumour and normal mucosa tissue as auxiliary covariate. From the 1000 CpG sites with the smallest adjusted p-value, 20 CpG sites with the smallest Brier score for overall survival (OS) were selected. Applying principal component analysis, we derived a prognostic methylation-based classifier for patients with non-metastatic CRC (ProMCol classifier). RESULTS: This classifier was associated with OS in the screening (HR 0.51, 95% CI 0.41 to 0.63, p=6.2E-10) and the validation cohort (HR 0.61, 95% CI 0.45 to 0.82, p=0.001). The independent validation of the ProMCol classifier revealed a reduction of the prediction error for 3-year OS from 0.127, calculated only with standard clinical variables, to 0.120 combining the clinical variables with the classifier and for 4-year OS from 0.153 to 0.140. All results were confirmed for disease-specific survival. CONCLUSION: The ProMCol classifier could improve the prognostic accuracy for patients with non-metastatic CRC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gündert M, Edelmann D, Benner A, et al. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). Gut. 2017. PMID: 29101262. doi:10.1136/gutjnl-2017-314711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。